Gilead Sciences' Kite completes acquisition of Tmunity

Published On 2023-02-26 06:00 GMT   |   Update On 2023-02-26 06:00 GMT

Santa Monica: Kite, a Gilead Company has announced the completion of the previously announced transaction to acquire Tmunity Therapeutics, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets,...

Login or Register to read the full article

Santa Monica: Kite, a Gilead Company has announced the completion of the previously announced transaction to acquire Tmunity Therapeutics, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.

The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets, platform capabilities, and a strategic research and licensing agreement with the University of Pennsylvania (Penn).

It will provide Kite with access to pre-clinical and clinical programs, including an ‘armored’ CAR T technology platform, which potentially could be applied to a variety of CAR T’s to enhance anti-tumor activity, as well as rapid manufacturing processes. In addition, as part of the acquisition, the Tmunity founders, who remain in their roles at Penn, will also provide consulting services to Kite as senior scientific advisors.

Read also: Kite Pharma, Daiichi Sankyo revise YESCARTA CAR T-Cell Therapy licensing agreement

The University of Pennsylvania’s Carl June, Bruce Levine, James Riley, Anne Chew were each individual equity holders in Tmunity and are now paid scientific advisors to Kite. Penn was also an equity holder in Tmunity. As inventors of some of the licensed technology, Drs. June, Levine, Riley, and Chew, along with Penn, may receive additional financial benefits under the license in the future.

Read also: USFDA approves Kite retroviral vector manufacturing facility in Southern California for commercial production

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer.




Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News